All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

N-acetyl-leucine has been used as an over-the-counter drug for the treatment of vertigo since 1957 \[[@pone.0229585.ref001]\]. Although the mechanism of action of N-acetyl-leucine for vertigo is not known, evidence implicates direct action on the central vestibular-related pathways and ocular motor networks \[[@pone.0229585.ref002],[@pone.0229585.ref003]\], as also demonstrated by \[^18^F\]fluorodeoxyglucose and Positron Emission Tomography \[[@pone.0229585.ref004]\]. At the molecular level, several mechanisms of action have been suggested including physicochemical partitioning into the phopspholipid bilayer to decrease its fluidity \[[@pone.0229585.ref001]\], direct action on glycine recptors and AMPA receptors \[[@pone.0229585.ref001]\], effects on branched chain aminotransferaes affecting glutamate neurotransmission \[[@pone.0229585.ref003]\], and an increase in glucose metabolism \[[@pone.0229585.ref003]\]. All of these mechanisms could contrribute to the observed effect of norrmalizing membrane potential and excitability leading to activation of the vestibulocerebellum and a deactivation of the posterolateral thalamus \[[@pone.0229585.ref002],[@pone.0229585.ref003],[@pone.0229585.ref005]\].

Recently, N-acetyl-leucine has experienced a renaissance with renewed interest from both academia and industry as a promising treatment for several disorders with unmet medical needs including cerebellar ataxia \[[@pone.0229585.ref003],[@pone.0229585.ref006]--[@pone.0229585.ref008]\], cognition and mobility in the elderly \[[@pone.0229585.ref009]\], lysosomal storage disorders \[[@pone.0229585.ref010],[@pone.0229585.ref011]\] migraine \[[@pone.0229585.ref012]\] and restless legs syndrome \[[@pone.0229585.ref013]\]. Given the broad therapeutic potential of N-acetyl-leucine, its pharmacodynamics and pharmacokinetics warrant further exploration.

As N-acetyl-leucine is an analogue of the alpha amino acid leucine, and because it retains leucine's stereocentre it exists as a pair of enantiomers ([Fig 1](#pone.0229585.g001){ref-type="fig"}). Enantiomers are isomers, compounds with the same molecular formula but which differ in the arrangement of their atoms in space, having one chiral stereocentre with four different substituents that yields two non-superimposable mirror image molecules ([Fig 1](#pone.0229585.g001){ref-type="fig"}). Often the pharmacological activity of a drug resides with a single enantiomer because living systems are chiral and formed from chiral constituents \[[@pone.0229585.ref014]\]. Thus, proteins encoded by mRNA and synthesized on ribosomes from L-amino acids are chiral and show stereoselective binding of drugs to transporters, receptors and enzymes \[[@pone.0229585.ref014]\]. Stereoselective binding can be trivial or profound: S-asparagine is sweet whereas R-asparagine is bitter; R-thalidomide is a sedative whereas the S-form is teratogenic \[[@pone.0229585.ref015]\]. The thalidomide tragedy shifted the importance of drug chirality from inconsequential to crucial \[[@pone.0229585.ref016]\] as reflected by the current requirements for developing single enantiomers in drug development and regulatory approval \[[@pone.0229585.ref017],[@pone.0229585.ref018]\].

![Chemical structure of N-acetyl-leucine.\
(**a**) Stereochemistry of the enantiomers. (**b**) Amide resonance structures showing similarity to an imine. Extending from the tetrahedral chiral carbon is a solid wedge to indicate a bond projecting above the plane of the paper and a hashed wedge to indicate a bond projecting below the plane of the paper.](pone.0229585.g001){#pone.0229585.g001}

The effects of chirality on drug behaviour has shifted from nice to know to effectively need to know basis for informed dosing and regulatory compliance, safety and efficacy. As N-acetyl-leucine was developed before realization of the importance of drug chirality, it was and continues to be used and marketed as a racemate (Tanganil^®^, Laboratoires Pierre Fabre)\[[@pone.0229585.ref001]\]. Subsequent studies in models of vertigo on the individual enantiomers have revealed that the therapeutic effects of N-acetyl-DL-leucine are due to the L-enantiomer \[[@pone.0229585.ref004],[@pone.0229585.ref019]\]. This means that, as expressed by Ariens \[[@pone.0229585.ref016]\] for chiral drugs in general, the racemic mixture (N-acetyl-DL-leucine) is in fact two drugs (the L-enantiomer and the D-enantiomer), each with distinct properties with one (N-acetyl-D-leucine) at best that does not contribute to the therapeutic response, and at worst potentially responsible for toxicity. Indeed, inclusion of an inactive enantiomer provides nothing but an impurity or 'isomeric ballast, as coined by Ariens \[[@pone.0229585.ref016],[@pone.0229585.ref020]\]. The resulting concern was stated by Lees et al. \[[@pone.0229585.ref021]\]: "An impurity at the level 50% of the active constituent would never be tolerated by regulatory authorities for any other constituent, which is neither an active, nor excipient nor solvent.".

Chirality affects not only the pharmacodynamic properties of potency, efficacy and affinity, it also affects pharmacokinetic processes of absorption, distribution, metabolism and excretion \[[@pone.0229585.ref021],[@pone.0229585.ref022]\]. Accordingly, both the US Food and Drug Administration's Guidance for Industry on the Development of New Stereoisomeric Drugs \[[@pone.0229585.ref017]\] and the European Medicines Agency \[[@pone.0229585.ref018]\] advises that when a single enantiomer has been found to be the pharmacologically active ingredient of a racemic mixture, it is important to not only characterize the pharmacokinetics of the active enantiomer, but also the effects of the inert member of the stereoisomer pair to determine if there are potential risks with administering the racemate, or benefits associated with the use of the single active enantiomer.

With the above as background regarding safety and efficacy of racemic drugs, and the fact that no data has been published on the pharmacokinetics of the enantiomers of N-acetyl-leucine, we investigated the pharmacokinetics of the racemate (an equal mixture of D and L) as well as the pharmacologically active L-enantiomer alone. We report significant and unexpected differences in the pharmacokinetics of the enantiomers.

Materials and methods {#sec002}
=====================

Animal ethics approval {#sec003}
----------------------

All experimental work in this study was conducted by Admescope Ltd. (Oulu, Finland) and was prospectively approved by the national Animal Experiment Board of Finland. The study was conducted under the project licence ESAVI/3047/04.10.07/2016, approved by the national Animal Experiment Board of Finland under Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes, with the following national provisions: Act (497/2013) and Decree (564/2013) on the Protection of Animals Used for Scientific or Educational Purposes (564/2013).

The Animal Welfare Body (AWB) of Admescope Ltd. oversees the animal care and use program. The activity of AWB is documented and it is monitored by the Provincial Veterinarian Officer. The Admescope laboratory Animal Unit is authorized, monitored and regularly inspected by the Regional State Administrative Agency of Southern Finland (Provincial veterinarian officer). The National Animal Experiment Board in Finland is responsible for the protocol review and authorisation. Approval number: ESAVI/3047/04.10.07/2016.

Details of animal welfare {#sec004}
-------------------------

Animals (5--8 weeks of age during the experiment) were purchased from Scanbur (Denmark) from Charles River Laboratories (Germany) and were housed in individually ventilated-cages in groups of six mice. The cages were provided with aspen bedding (4HP and PM90L, Tapvei, Estonia) and paper strands (Sizzlenest, Datesand, UK) as nesting material, and a paper pulp cabin and red polycarbonate cylinder (Datesand, UK) as cage enrichment. The temperature (22 ± 2°C), humidity (55 ± 10%) and air exchange rate (75 (times/h) of the individually ventilated-cages and 12/12-h light/dark cycle (500 lux lighting on at 6 am, 1.5 lux lighting on at 6 pm) of the animal holding room were automatically controlled and maintained. Animals were allowed to acclimatize to the site for at least five days prior to the study. Animals had *ad libitum* access to food (SDS diets, RM1 (E) 801002, Special Diets Services, UK) and tap water at all times, and their welfare was assured with daily observations.

To minimize animal suffering and distress, clinical signs and general behaviour of the animals were recorded when necessary. Noninvasively monitoring enables detection of any signs that a drug was not well tolerated in this species and strain. Note that no adverse effects were noted. The animals were not anesthetized during administration of study formulations or during blood sampling, as the pain inflicted by these procedures is considered as minor. Additionally, the following internationally acknowledged primary standards, regulations, recommendations and legislation are applied to the institutional animal care and use program to support animal welfare, acknowledging 3R principles and transparency at Admescope Ltd: 1, European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes, Council of Europe (ETS 123); 2, The Guide for the Care and Use of Laboratory Animals, NRC, 2011; 3, FELASA Guidelines and Recommendations; 4, Directive 2010/63/EU; and 5, National Centre for the replacement, refinement and reduction of animals in research recommendations (NC3Rs).

In the case where only plasma and no tissue samples were collected, the animals were killed humanely by using CO~2~, followed by cervical dislocation as described in the animal ethics approval held by Admescope. When both plasma and tissue samples were collected, the animals were killed under isoflurane anaesthesia via cervical dislocation.

We used male BALB/c mice because this inbred strain of mice as it is commonly used for preclinical pharmacokinetic studies \[[@pone.0229585.ref023]\]. Mice are commonly used because of their short lifespan, allowing for the growth of a large number of animals in a short period of time and, consequently, the feasibility of many studies to predict pharmacokinetic profiles in humans \[[@pone.0229585.ref024]\]. We used male mice as this is the sex that is most commonly used; however, we note that sex differences have been reported \[[@pone.0229585.ref025]\] and this could be investigated in the future for N-acetyl-leucine. Pharmacokinetic data obtained from mice can be used to extrapolate to humans through allometric scaling, but differences between specific drugs require empirical studies in humans \[[@pone.0229585.ref026]\].

The animals were weighed on the day prior to dosing. The compound was administered to male BALB/c mice (n = 3 per time point) p.o. (100 mg/kg; 10 mL/kg) by oral gavage. Blood samples were collected into potassium EDTA tubes by venepuncture from the saphenous vein. Within 30 min following the sampling, blood was centrifuged for plasma separation (room temperature; 10 min; 2700 x*g*). The plasma samples were transferred into plastic tubes, frozen and stored at --20°C.

Chemicals and suppliers {#sec005}
-----------------------

HPLC grade methanol and acetonitrile were from Merck (Darmstadt, Germany). HPLC grade formic acid, acetic acid and ammonium formate were from BDH Laboratory Supplies (Poole, UK). Other chemicals were from Sigma Aldrich (Helsinki, Finland), and of the highest purity available. Water was from a Direct-Q3 (Millipore Oy, Espoo, Finland) purification system and UP grade (ultrapure, 18.2 MW). N-acetyl-DL-leucine was obtained from Molekula (\#73891210) and N-acetyl-L-leucine was obtained from Sigma Aldrich (\#441511).

Sample preparation {#sec006}
------------------

The plasma samples were prepared for analysis by mixing 50 μL of plasma with 100 μL of acetonitrile and mixed. In addition to plasma, skeletal muscle and brain tissue was also taken at less frequent time points (0.5, 2, 6, 24 and 48 h) and prepared for analysis by homogenization of 50 mg of tissue with 100 μL of acetonitrile. The samples were transferred to Waters 96-well plate and the sample was evaporated under nitrogen gas flow. The sample was reconstituted into 150 μl of 50% methanol:water and analysed by LC/MS. Standard plasma samples were prepared by spiking the injection solution with concentrations from 1 to 10 000 ng/mL by using one volume of spiking solution and nine volumes of injection solution. These samples were then prepared for analysis in the same way as the samples. Quality control (QC) samples were prepared both from racemic-N-Acetyl-Leucine and from N-Acetyl-L-Leucine in two different concentrations. QC samples from racemic-N-Acetyl-Leucine were prepared into concentrations of 40, 400 and 4000 ng/mL, corresponding to 20, 200 and 200 ng/mL concentration of both D- and L-enantiomers, respectively. QC samples of N-Acetyl-L-Leucine was then prepared into concentrations of 20, 200 and 2000 ng/mL. QC samples were then prepared for analysis in the same way as the samples.

Quantification with liquid chromatography-mass spectrometry and chiral-HPLC {#sec007}
---------------------------------------------------------------------------

Quantification by HPLC was performed using a Supelco Astec CHIROBIOTIC T chiral HPLC column (2.1 x 150 mm, 5 μm particle size) with a Waters Acquity UPLC + Thermo Q-Exactive hybrid Orbitrap MS, using ESI negative polarity, nitrogen auxiliary gas (450°C), capillary voltage was 2000 and 350°C and controlled with the software Xcalibur 4.1. Samples were injected as a 4-μL volume and eluted with a gradient of buffer A (20 mM ammonium acetate) and buffer B (methanol) with a flow rate of 0.3 mL/min and column oven temperature of 30°C. The gradient was 80% A at 0 min; 20% A at 3.5 min and 80% A at 4.5 min Parallel Reaction Monitoring (PRM) and Full-MS-dd-MS2 were measured at the same time. In PRM, quadrupole was used as a mass filter and depending whether deuterated or non-deuterated N-Acetyl-L-Leucine was detected, either m/z 172 or 176 only got through. Ions with aforementioned m/z was then collided and leucine fragment (m/z 130 or 134) was used in quantitation. In full-MS-dd-MS2 mode, every ion with intensity over a certain intensity was collided and fragments analyzed.

Metabolite identification with reverse phase ultrahigh performance liquid chromatography {#sec008}
----------------------------------------------------------------------------------------

Metabolite identification was performed using a Waters Acquity UPLC + Thermo Q-Exactive hybrid Orbitrap MS and a Waters Acquity HSS T3 column (50 x 2.1 mm, 1.8 μm particle size). MS was as described above over the mass range of 70--1000 using an acquisition time of 7 Hz for full scan, IT 100 ms for DDI MS/MS, an AGC Target of 1E6, maximum IT of 100 ms and 35 000 (FWHM @ m/z 200) for full scan, 17 500 for MS/MS in DDI mode off for full scan; 20+40+60 for DDI MS/MS inclusion list for expected metabolites ON; also other unexpected most abundant metabolites chosen for MS/MS. Samples were injected as a 4-μL volume and eluted at a flow rate of 0.5 mL/min and a column oven temperature of 35°C with a gradient consisting of Buffer A 0.1% formic acid and Buffer B acetonitrile. The gradient was (min, %A): 0, 98; 0.5, 98; 2, 50; 3, 5 and 3.5, 5. Ion chromatograms were extracted from the total ion chromatograms using calculated monoisotopic accurate masses with 10 mDa window. The metabolites were mined from the data using software-aided data processing (Thermo Compound Discoverer 2.0 including structure-intelligent dealkylation tool & mass defect filter) with manual confirmation.

Pharmacokinetic calculations {#sec009}
----------------------------

Plasma pharmacokinetic parameters of the N-acetyl-leucine enantiomers were calculated using Phoenix 64 (Build 6.4.0.768) WinNonlin (version 6.4) software, using non-compartmental method with sparse sampling. Nominal doses were used for all animals. The terminal phase half-life (T~1/2~), the time for 50% of the plasma concentration to decrease after some point of elimination, was calculated by least-squares regression analysis of the terminal linear part of the log concentration--time curve using the relationship 0.693/k~e~. The area under the plasma concentration--time curve (AUC), an estimation of plasma drug exposure over time, was determined with the linear trapezoidal rule for increasing values and log trapezoidal rule for decreasing values up to the last measurable concentration (AUC~0-last~). The first order elimination rate constant k~e~ was calculated as the slope (minimum 3 points) from the terminal log plasma concentration time curve. The maximum concentration (C~max~) and the time taken to achieve the peak concentration (T~max~) after oral dose were obtained directly from the plasma concentration data without interpolation. The theoretical background and interpretation of the pharmacokinetic data was based on \[[@pone.0229585.ref023]\]. Where appropriate, data are expressed as the mean ± standard error of the mean. Means were statistically analysed by either pre-planned t tests or a one-sample t test comparing the measured value with the expected value. Graphs were plotted using Prism 7 (GraphPad Software Inc) and organized and formatted in Illustrator (Adobe Inc).

Results {#sec010}
=======

N-acetyl-D-leucine exhibits larger C~max~ and AUC following racemate administration {#sec011}
-----------------------------------------------------------------------------------

To determine whether the enantiomers of N-acetyl-leucine have different pharmacokinetics, we orally dosed mice with either a racemate or the L-enantiomer ([Fig 2](#pone.0229585.g002){ref-type="fig"} and [S1 Fig](#pone.0229585.s001){ref-type="supplementary-material"}). Following an oral dose of N-acetyl-DL-leucine (100 mg/kg and 10 mg/mL), in the plasma, the concentration of the D-enantiomer was greater than the L-enantiomer at all time points ([Fig 3A](#pone.0229585.g003){ref-type="fig"}). Note that direct comparison of the enantiomers is shown in replots of these data ([Fig 4](#pone.0229585.g004){ref-type="fig"}) and will be discussed below. This asymmetry in the plasma concentrations of the D- and L-enantiomers can be quantitated by comparing, respectively, C~max~ of 86100 ng/mL verses 341 ng/mL ([Fig 5A](#pone.0229585.g005){ref-type="fig"} and [Table 1](#pone.0229585.t001){ref-type="table"}) and AUC of 75800 h\*ng/mL versus 2560 h\*ng/mL ([Fig 5D](#pone.0229585.g005){ref-type="fig"} and [Table 1](#pone.0229585.t001){ref-type="table"}). The elimination rate was similar for both enantiomers, indicated by the linear and parallel curves on a semilog graph ([Fig 3B](#pone.0229585.g003){ref-type="fig"}) using a noncompartmental model giving a k~e~ of 2.2 h^-1^ for the D-enantiomer and 2.8^−1^ h for L-enantiomer ([Fig 5C](#pone.0229585.g005){ref-type="fig"} and [Table 1](#pone.0229585.t001){ref-type="table"}), with corresponding T~1/2~ values of 0.31 h and 0.40 h ([Fig 5E](#pone.0229585.g005){ref-type="fig"} and [Table 1](#pone.0229585.t001){ref-type="table"}). The D-enantiomer remained detectable until 8 h ([Fig 5G](#pone.0229585.g005){ref-type="fig"}) with the last concentration of 247 ng/mL ([Fig 5F](#pone.0229585.g005){ref-type="fig"}). In contrast, the L-enantiomer remained detectable until 2 h ([Fig 5G](#pone.0229585.g005){ref-type="fig"}) with the last concentration of 623 ng/mL ([Fig 5F](#pone.0229585.g005){ref-type="fig"}).

![Schematic outlining the experimental procedure.\
Male mice were orally administered N-acetyl-leucine as either the racemate (50% each enantiomer) or purified L-enantiomer (2.6% D-enantiomer and 97.4% L-enantiomer). At specific times (0.25 to 8 h) after administration, blood was taken, plasma was separated and quantified by chiral liquid chromatography/mass spectrometry. Plots of the plasma concentration of each enantiomer over time were used to visualize pharmacokinetics and a noncompartmental model was used to calculate the pharmacokinetic parameters C~max~ (maximum peak concentration), T~max~ (time to reach C~max~), k~e~ (first order elimination rate constant), T~1/2~ (half-life) and AUC (area under the curve). Samples of brain and skeletal muscle were also taken at specific times and used to determine compound distribution and to search for metabolites with high-resolution mass spectrometry.](pone.0229585.g002){#pone.0229585.g002}

![Graphs of plasma concentration of enantiomers versus time after administration of racemic N-acetyl-DL-leucine or purified N-acetyl-L-leucine.\
Data are presented as (**a,c**) linear-linear plots or (**b,d**) semilog plots. Values are the mean ± standard error of the mean with n = 3 (mice).](pone.0229585.g003){#pone.0229585.g003}

![Replots of the data to facilitate direct comparison of the plasma concentration of N-acetyl-leucine enantiomers after oral administration of racemic N-acetyl-DL-leucine or purified N-acetyl-L-leucine.\
Data are presented as (**a,c**) linear-linear plots or (**b,d**) semilog plots. Values are the mean ± standard error of the mean with n = 3 (mice).](pone.0229585.g004){#pone.0229585.g004}

![Bar charts showing the pharmacokinetic parameters for the enantiomers of N-acetyl-L-leucine after administration of racemic N-acetyl-DL-leucine (denoted as DL) or N-acetyl-L-leucine (denoted as L).\
(**a-g**) Conventional pharmacokinetic parameters calculated from the plasma concentration of drug. (**h-j**) Parameters derived from the conventional pharmacokinetic parameters to detect and highlight the effects of pharmacokinetic differences between the enantiomers. Values are the mean ± standard error of the mean with n = 3 (mice). Means were statistically analysed by either (**a-g**) pre-planned t tests; (**h and i**) a one-sample t test comparing the measured value with the expected value: 1 when administered as DL and 36 when administered as purified L; and (**j**) a one-sample t test comparing the measured value with the expected value of 2. The means compared are indicated by the horizontal lines on the charts, and exact p values are provided for the comparisons.](pone.0229585.g005){#pone.0229585.g005}

10.1371/journal.pone.0229585.t001

###### The calculated pharmacokinetic parameters for N-Acetyl-D-Leucine and N-Acetyl-L-Leucine plasma after oral administration of N-Acetyl-DL-Leucine or N-Acetyl-L-Leucine at a nominal dose of 100 mg/kg.

![](pone.0229585.t001){#pone.0229585.t001g}

  Compound administered                                      N-Acetyl-DL-Leucine   N-Acetyl-L-Leucine                     
  ---------------------------------------------------------- --------------------- -------------------- -------- -------- --------
  r^2^                                                       \-                    0.91                 0.93     0.85     0.72
  k~e~                                                       \-                    2.2                  2.8      1.7      2.4
  T~max~                                                     h                     \<0.25               \<0.25   \<0.25   \<0.25
  C~max~                                                     ng/mL                 86 100               3410     436      16 800
  T~last~                                                    h                     8.00                 2.00     8.00     6.00
  C~last~                                                    ng/mL                 247                  623      16.2     168
  T~1/2~                                                     h                     0.31                 0.4      0.25     0.29
  AUC~0-last~                                                h x ng/mL             57 800               2 560    573      11 400
  Ratio C~max~ L/D [^\#^](#t001fn001){ref-type="table-fn"}   \-                    0.04                          38.5     
  Ratio AUC L/D [^\#^](#t001fn001){ref-type="table-fn"}      \-                    0.04                          19.8     

^\#^The ratio of corresponding value between L and D enantiomers

Pharmacokinetics of the enantiomers following N-acetyl-L-leucine administration {#sec012}
-------------------------------------------------------------------------------

For oral dosing with purified N-acetyl-L-leucine, the commercial source of this was found to contain 97.4% L-enantiomer and 2.6% of the D-enantiomer ([S1 Fig](#pone.0229585.s001){ref-type="supplementary-material"}). This trace contamination enabled us to evaluate the pharmacokinetics of the D-enantiomer at a much lower dose, and allowed for an internal control and comparator. Following an oral dose of the purified L-enantiomer at 100 mg/kg and 10 mg/mL, the concentration of the L-enantiomer was greater at all time points ([Fig 3C](#pone.0229585.g003){ref-type="fig"}). Quantitatively, for the D- and L-enantiomers, respectively, had a C~max~ of 436 ng/mL versus 16900 ng/mL ([Fig 5A](#pone.0229585.g005){ref-type="fig"} and [Table 1](#pone.0229585.t001){ref-type="table"}) and an AUC of 573 h\*ng/mL and 11400 h\*ng/mL ([Fig 5D](#pone.0229585.g005){ref-type="fig"} and [Table 1](#pone.0229585.t001){ref-type="table"}). As with administration of the racemate ([Fig 3A and 3B](#pone.0229585.g003){ref-type="fig"}), after dosing with purified L-enantiomer, the elimination rate was similar for both enantiomers, indicated by the linear and parallel curves on a semilog graph ([Fig 3D](#pone.0229585.g003){ref-type="fig"}) and was well-fit with a noncompartmental model giving a k~e~ of 1.7 h^-1^ for the D-enantiomer and 2.4^−1^ for L-enantiomer ([Fig 5C](#pone.0229585.g005){ref-type="fig"} and [Table 1](#pone.0229585.t001){ref-type="table"}), with corresponding T~1/2~ values of 0.25 h and 0.29 h ([Fig 5E](#pone.0229585.g005){ref-type="fig"} and [Table 1](#pone.0229585.t001){ref-type="table"}). Both enantiomers remained detectable in the plasma until 8 h and 6 h ([Fig 5G](#pone.0229585.g005){ref-type="fig"}) with a last concentration of 16 ng/mL and 168 ng/mL ([Fig 5F](#pone.0229585.g005){ref-type="fig"}). However, the C~last~ and T~last~ are somewhat misleading for all measurements, as in looking at the profiles, the main elimination was over for all enantiomers at around 4 h when these terminal concentrations were reached ([Fig 3B and 3D](#pone.0229585.g003){ref-type="fig"}).

Dose proportionality is greater than unity {#sec013}
------------------------------------------

Dose proportionality refers to the effect of an increase in dose on C~max~ and AUC \[[@pone.0229585.ref023]\]. We can assess dose proportionality with our data by using the amount of each enantiomer present in the composition administered. The D-enantiomer was dosed as 50% of the administered racemate and as 2.6% of the administered purified L-enantiomer, for a difference in dose proportionality of 19-fold. The actual dose proportionality was 197-fold for C~max~ (86100/436; [Table 1](#pone.0229585.t001){ref-type="table"}) and 101 fold for AUC (57800/573; [Table 1](#pone.0229585.t001){ref-type="table"}). The L-enantiomer was dosed as 50% of the administered racemate and 97.4% of the administered purified L-enantiomer, for a difference in dose proportionality of 1.9-fold. The actual dose proportionality was 4.9-fold for C~max~ (16800/3410; [Table 1](#pone.0229585.t001){ref-type="table"} and [Fig 5J](#pone.0229585.g005){ref-type="fig"}) and 4.6 fold for AUC (11400/2560; [Table 1](#pone.0229585.t001){ref-type="table"} and [Fig 5J](#pone.0229585.g005){ref-type="fig"}).

Direct comparison of enantiomers highlights pharmacokinetic differences {#sec014}
-----------------------------------------------------------------------

To facilitate comparison of the racemate with the purified L-enantiomer, we re-plotted the plasma concentration versus time profiles of the two enantiomers on the same graph over the first two hours ([Fig 4](#pone.0229585.g004){ref-type="fig"}). The amount of D-enantiomer in the plasma is significantly higher when dosed with the racemate compared to the much lower amount present when dosed with purified L-enantiomer, and is consistent with the measured 2.6% D contamination in the purified L-enantiomer ([S1 Fig](#pone.0229585.s001){ref-type="supplementary-material"}). The semilog plot nicely shows the equal rates of elimination at all concentrations and times, demonstrating that the D-enantiomer is not affected by dosing with either the DL or L form. As would be expected with administering a 97.4% to 2.6% mixture of N-acetyl-L-leucine to N-acetyl-D-leucine, the L-enantiomer dominated in the plasma ([Fig 4A and 4B](#pone.0229585.g004){ref-type="fig"}). Administration of DL or L alone only affected C~max~ and AUC, but did not affect elimination (k~e~ o T~1/2~). Plotting the L-enantiomer in the plasma on the same graph to compare dosing with DL with L alone ([Fig 4C](#pone.0229585.g004){ref-type="fig"}), graphically shows the dramatic differences in C~max~ and AUC, but show the same rate of elimination (parallel curves when fit to a noncompartmental model).

Another way to compare administration of the racemate to the purified L-enantiomer on the pharmacokinetics of the enantiomers was to calculate the ratio of enantiomers in regard to C~max~ and AUC. As we verified the administered compound to be a true racemate (50% each enantiomer; [S1 Fig](#pone.0229585.s001){ref-type="supplementary-material"}), deviations from a ratio of 1 reveal significantly different pharmacokinetics between the D- and L-enantiomers. When administered as the racemate, the ratio of D/L enantiomer was about 25 for both C~max~ ([Fig 5H](#pone.0229585.g005){ref-type="fig"}; 26 versus 1, p = 0.014) and AUC ([Fig 5I](#pone.0229585.g005){ref-type="fig"}, 25 vs 1, p = 0.015). As the purified L-enantiomer administered contained 97.4% L-enantiomer and 2.6% D-enantiomer ([S1 Fig](#pone.0229585.s001){ref-type="supplementary-material"}), if the enantiomers had identical pharmacokinetics, the ratio of L/D would be predicted to be 36 (that is, 97.4/2.6). When administered as the purified L-enantiomer, the ratio of L/D was 32 for C~max~ ([Fig 5H](#pone.0229585.g005){ref-type="fig"}; 31.7 versus 36, *p* = 0.17) and 20 for AUC ([Fig 5I](#pone.0229585.g005){ref-type="fig"}; 19.8 versus 36, *p* = 0.006).

Enantiomers show differences in distribution and metabolism {#sec015}
-----------------------------------------------------------

To investigate the effect of administering either the racemate or purified L-enantiomer of N-acetyl-leucine on the distribution of the enantiomers, muscle and brain were analysed. At specific times after oral dosing, the mice were euthanized and the amount of D- and L-enantiomer present in the tissues was determined. Following oral dosing with the racemate, muscle contained much more D-enantiomer than L-enantiomer ([Fig 6A](#pone.0229585.g006){ref-type="fig"}). In muscle, the D-enantiomer was only detectable at 30 min and 2 h ([Fig 6A](#pone.0229585.g006){ref-type="fig"}). In contrast, following oral dosing of the L-enantiomer alone, in muscle, the L-enantiomer was not detected at any time point and the D-enantiomer was detectable but at a much lower concentration ([Fig 6C](#pone.0229585.g006){ref-type="fig"}) than after administration of the racemate ([Fig 6A](#pone.0229585.g006){ref-type="fig"}). Neither the D- nor L-enantiomer was detected in muscle after 2 hours from the time or dosing ([Fig 6A and 6C](#pone.0229585.g006){ref-type="fig"}). Following oral dosing with the racemate, the brain contained detectable D-enantiomer at only the 30 min time point and L-enantiomer was not detectable at any time point ([Fig 6B](#pone.0229585.g006){ref-type="fig"}). Following oral dosing with purified L-enantiomer, neither of the enantiomers were detected at any time point ([Fig 6D](#pone.0229585.g006){ref-type="fig"}).

![Graphs of the concentration of enantiomers in tissue versus time after administration of racemic N-acetyl-DL-leucine or purified N-acetyl-L-leucine.\
Data are for (**a,b**) muscle and (**c,d**) brain and presented as linear-linear plots. Values are the mean ± standard error of the mean with n = 3 (mice).](pone.0229585.g006){#pone.0229585.g006}

We investigated the identity of the metabolites of both enantiomers in muscle, but no metabolites of either N-acetyl-D-leucine or N-acetyl-L-leucine were detected (data not shown).

Discussion {#sec016}
==========

We investigated the pharmacokinetics of the enantiomers of N-acetyl-leucine after oral administration of the racemate, which has been marketed under the name Tanganil^®^ for the treatment of vertigo in France since 1957 \[[@pone.0229585.ref001]\], and the purified L-enantiomer, which is the pharmacologically active enantiomer in models of acute vertigo \[[@pone.0229585.ref004],[@pone.0229585.ref019]\]. We report significant and unexpected differences in the pharmacokinetics of the enantiomers. The major findings of this study are as follows: First, when administered as the racemate (N-acetyl-DL-leucine), the D-enantiomer was present at much higher plasma maximal concentration (C~max~) and (area under the curve; AUC) relative to the L-enantiomer, resulting in greater total exposure. Second, when administered as purified N-acetyl-L-leucine, both the C~max~ and the AUC for N-acetyl-L-leucine were higher compared to administration as the racemate, even when scaled for the relative dose. Third, both enantiomers distributed to the tissues monitored, muscle and brain, but the D-enantiomer was found at much higher concentrations relative to the L-enantiomer in both tissues.

Origin of the differences in C~max~ and AUC {#sec017}
-------------------------------------------

The larger AUC for N-acetyl-L-leucine when administered as the purified enantiomer compared to when administered as the racemate, and factoring in the actual amounts of L-enantiomer present in each (that is, 97.6% and 50%, respectively), is fully accounted for the by increase in C~max~ because after C~max~ and T~max~, the clearance (k~e~ and T~1/2~) is the same for both enantiomers. In other words, after 15 min, the pharmacokinetic parameters are the same for both enantiomers. Therefore, the large differences in C~max~ have to be due to processes occurring in the first 15 min and before the L-enantiomer enters the plasma. Consequently, we can deduce that the D-enantiomer is interfering with the bioavailability (the amount of drug orally administered that is systemically available) of the L-enantiomer during the first 15 min following oral administration. Differences between enantiomers indicate interaction with protein targets; therefore, two possible explanations that are not mutually exclusive exist: competition at a carrier on cells in the intestine and/or differences in first-pass metabolism.

Stereoisomer-mediated pharmacokinetics arising from uptake {#sec018}
----------------------------------------------------------

The bioavailability of a drug is determined by its ability to penetrate and cross the gastrointestinal epithelial cell membrane, either by passive diffusion or via a carrier. Uptake by passive diffusion is determined by physicochemical properties, primarily hydrophobicity, which allows penetration of the membrane's core \[[@pone.0229585.ref027],[@pone.0229585.ref028]\]. The N-acetylation of leucine would be predicted to greatly increases passive membrane transport, as it eliminates one (NH~3~^+^) of the two (NH~3~^+^ and COO^-^) charges present on all amino acids at physiological pH, which can increase transport rates up to 10^10^-fold \[[@pone.0229585.ref029],[@pone.0229585.ref030]\]. However, as this physicochemical effect (loss of charge and increase in hydrophobicity) is identical for the enantiomers, it cannot underlie the differences observed in the pharmacokinetics of the N-acetyl-leucine enantiomers. In contrast, uptake by carriers requires molecular recognition at saturable binding sites and would give rise to interference between the enantiomers. The identity of the carrier for N-acetyl-leucine on the intestinal brush-border membrane is unknown; however, given that N-acetyl-leucine is a modified amino acid, the most likely candidates are amino acid transporters, as 52 families exist that show distinct substrate selectivity\[[@pone.0229585.ref031]--[@pone.0229585.ref033]\]. These possibilities can be narrowed down further based on the effect of N-acetylation, which forms an amide bond ([Fig 1](#pone.0229585.g001){ref-type="fig"}). An amide bond would both make N-acetyl-leucine appear more like a dipeptide and, through resonance, given the C-N bond partial double bond character with a bond order 1.5 \[[@pone.0229585.ref034]\], making it an analogue of an imine ([Fig 1B](#pone.0229585.g001){ref-type="fig"}). These predict that N-acetyl-leucine would be a substrate for the low affinity/high capacity a H^+^-coupled di/tripeptide transporter termed PepT1, which is highly expressed and responsible for 80% of all amino acids are taken up from the small intestine lumen, or an imino acid transporter which has 100-fold greater affinity for N-modified amino acids and shows only 2-fold stereoselectivity \[[@pone.0229585.ref035]\].

Stereoisomer-mediated pharmacokinetics arising from first-pass metabolism {#sec019}
-------------------------------------------------------------------------

Another likely contributing process accounting for the differences between enantiomers in C~max~ and AUC is first-pass metabolism \[[@pone.0229585.ref021]\]. As first-pass metabolism is an enzymatic process, it exhibits molecular recognition at saturable binding sites and would also give rise to interference between the enantiomers. Such stereoselective first-pass effects are known to alter oral drug bioavailability of the enantiomers of propranolol and verapamil \[[@pone.0229585.ref022],[@pone.0229585.ref036]\]. Indeed, the 2-3-fold stereoisomer effect we detected for N-acetyl-leucine is similar to the 2--3 fold greater oral bioavailability of (--)-verapamil compared to (+)-verapamil caused by first-pass metabolism \[[@pone.0229585.ref021]\]. Most often first-pass metabolism is mediated by cytochrome P-450 oxidation in the stomach, intestine or liver \[[@pone.0229585.ref021]\]; however, N-acetyl-L-leucine is more likely handled like a nutrient than a xenobiotic, as it is a naturally occurring metabolite of L-leucine and a transacetylase has been reported that interconvert N-acetyl-L-leucine and L-leucine, using other L-amino acids as the substrate or product \[[@pone.0229585.ref037],[@pone.0229585.ref038]\]. Therefore, a likely enzyme for first-pass metabolism of N-acetyl-L-leucine would be the acylase reported in intestinal strips that was able to remove the acetyl group from most amino acids \[[@pone.0229585.ref039]\], and showed 40,000-fold selectivity for L-amino acids over D-amino acids \[[@pone.0229585.ref037]--[@pone.0229585.ref040]\].

Stereoisomer effects manifested by tissue uptake and metabolism {#sec020}
---------------------------------------------------------------

In regard to the presence of the enantiomers in muscle and brain, the amounts were much lower than in the plasma (10-fold to undetectable), and the D-enantiomer was present at a much higher concentration than the L-enantiomer. In general, our results showing that N-acetyl-leucine is blood-brain barrier permeable are consistent with studies in monkeys in which radioactive racemic N-acetyl-leucine was administered intravenously and radioactivity was subsequently detected in the brains \[[@pone.0229585.ref041]\]. However, the ^14^C label was in the alpha carbon of leucine and autoradiography was used for quantification, so there is no ability to determine whether the radioactivity was due to N-acetyl-DL-leucine itself or a metabolite \[[@pone.0229585.ref041]\]. Therefore, the data with radioactivity is ambiguous in terms of both the effect of stereoisomerism and whether N-acetylation promotes uptake and whether it is rapidly metabolized to L-leucine.

In contrast to the situation with uptake from the gut to the plasma in which the D-enantiomer was reducing uptake, in muscle and brain, the presence of the D-enantiomer was associated with increased presence of N-acetyl-L-leucine. Uptake from the plasma into cells and tissues, as described for the intestinal cells above, occurs through both passive diffusion and carriers. The explanation of competitive inhibition for a common carrier used for the asymmetry in uptake between the enantiomers into the plasma of competition cannot explain this observation. Indeed, such an effect would result in less of the L-enantiomer, not more, when N-acetyl-D-leucine was also present. A more likely explanation is competitive inhibition of the enantiomers at an enzyme that metabolizes N-acetyl-L-leucine. A likely explanation is that the D-enantiomer is inhibiting the deacetylation of N-acetyl-L-leucine. It is also important to note that the amount of N-acetyl-L-leucine in tissues is a steady state measure of the compound, and relates not to lack of uptake but rather rapid utilization. By comparison, the D-enantiomer was present in higher amounts, consistent with it being metabolically inert based on feeding N-acetyl-D-leucine to rats, where it was excreted in the urine unchanged \[[@pone.0229585.ref038]\]. The simplest explanation is that the N-acetyl-L-leucine is rapidly converted to L-leucine and utilized in metabolism. Rapid utilization and metabolism of L-leucine is consistent with the results of a study using stable isotope-labelled leucine itself upon oral administration \[[@pone.0229585.ref042]\]. Moreover, our inability to detect metabolites is consistent with the disappearance of N-acetyl-L-leucine though metabolism to L-leucine, which would be undetectable on the background of endogenous L-leucine. Slowing the conversion of N-acetyl-L-leucine to L-leucine, and subsequently its regulatory effect on muscle protein synthesis and oxidative metabolism \[[@pone.0229585.ref043],[@pone.0229585.ref044]\], and possibly impact on its efficacy as a drug. Taken together, these data showing low amounts of N-acetyl-leucine in the brain and muscle suggest that the mechanism of action of N-acetyl-L-leucine requires metabolism.

Clinical implications of stereoselective pharmacokinetics {#sec021}
---------------------------------------------------------

The different pharmacokinetics of the enantiomers would conceivably result in disproportionate total exposure (increase in the AUC) to the D-enantiomer when the racemate is dosed, as the L-enantiomer would be eliminated much faster. Importantly, chronic treatment with multiple doses over time would cause accumulation in the body of the D-enantiomer of N-acetyl-leucine. Historically, it was presumed that the 'inactive' enantiomer was harmless \[[@pone.0229585.ref016]\], a notion disabused by the thalidomide tragedy \[[@pone.0229585.ref015]\]. Although the N-acetyl-D-leucine is not reported to be toxic, concerns about the toxicity of D-amino acids in general have been raised as the reason for the original evolutionary selection and biological presence of D-amino acid oxidase \[[@pone.0229585.ref045],[@pone.0229585.ref046]\]. Evidence that the D-leucine is having a biological effect comes from a report in which low amounts (about 1/10th of endogenous L-form) of D-leucine suppressed endogenous levels of L-leucine by almost half \[[@pone.0229585.ref047]\].

Conclusions {#sec022}
===========

In conclusion, firstly, the L-enantiomer--which is the pharmacologically active form in models of acute vertigo--has different pharmacokinetics when administered with the D-enantiomer as the racemate (N-acetyl-DL-leucine) compared to administration as the purified L-enantiomer. Secondly, we found evidence for an accumulation of the D-enantiomer, which would be exacerbated by chronic dosing of the racemate, with unknown and possibly unwanted deleterious effects on cell function. Thirdly, the results of this study, taken together with the regulatory guidelines of the FDA \[[@pone.0229585.ref017]\] and the EMA \[[@pone.0229585.ref018]\], strongly supports the research and development of isolated N-acetyl-L-leucine.

Supporting information {#sec023}
======================

###### Chiral high performance liquid chromatography/mass spectrometry analysis showing separation and quantification of the compounds used in these studies.

(**a**) Spectrum of racemate. (**b**) Spectrum of purified N-acetyl-L-leucine. Note that the peak areas are not directly comparable with concentration due to differences in the extent of ionization of the compound in the mass spectrometers ionization chamber due to relative differences in aqueous and organic solvent concentrations in the mobile phase at those time points due to a gradient elution. Therefore, quantification was based on a standard curve specific to each enantiomer. The result is that the racemate contained 50.2% N-acetyl-D-leucine and 49.8% N-acetyl-L-leucine. The purified N-acetyl-L-leucine contained 2.6% N-acetyl-D-leucine and 97.4% N-acetyl-L-leucine. The limit of detection and the limit of quantification was, respectively, 10 ng/mL and 25 ng/mL for N-acetyl-D-leucine, and 25 ng/mL and 50 ng/mL for N-acetyl-L-leucine.

(TIF)

###### 

Click here for additional data file.

###### Measured concentrations of N-Acetyl-L-Leucine and N-Acetyl-D-Leucine in mouse plasma and tissues after p.o administration N-Acetyl-DL-Leucine at 100 mg/kg.

(DOCX)

###### 

Click here for additional data file.

###### Measured concentrations of N-Acetyl-L-Leucine and N-Acetyl-D-Leucine in mouse plasma and tissues after p.o administration N-Acetyl-L-Leucine at 100 mg/kg.

(DOCX)

###### 

Click here for additional data file.
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Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.

• A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.

• An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Nicolás Pérez-Fernández

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response: We confirm that our manuscript meets PLOS ONE's style requirements.

2\. At this time, we request that you please report additional details in your Methods section regarding animal care, as per our editorial guidelines. In the cases where mice were euthanized using CO2 asphyxiation (no samples collected), please state whether a secondary method of euthanasia was used to ensure the humane sacrifice of the mice.

Response: We have reworded the section to clarify our meaning and added that cervical dislocation was also used for these animals. We have added this in lines 190-192 in the revised manuscript.

3\. Thank you for stating the following in the Competing Interests section:

\"I have read the journal\'s policy and the authors of this manuscript have the following competing interests: MS is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker's honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. He is a shareholder of IntraBio. He acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion. GCC, AG and FP are cofounders, shareholders and consultants to IntraBio. FP is a consultant to Actelion. IntraBio Ltd is the applicant for patents WO2018229738 (Treatment For Migraine), WO2017182802 (Acetyl-Leucine Or A Pharmaceutically Acceptable Salt Thereof For Improved Mobility And Cognitive Function), WO2019078915 and WO2018029658 (Therapeutic Agents For Neurodegenerative Diseases), WO2018029657 (Pharmaceutical Compositions And Uses Directed To Lysosomal Storage Disorders), and WO2019079536 (Therapeutic Agents For Improved Mobility And Cognitive Function And For Treating Neurodegenerative Diseases And Lysosomal Storage Disorders).\"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Response: We have added the requested statement and included this text in our cover letter.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Response: Our statement complies with PLOS ONE's policy.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

Response: We have added all the underlying raw data in the form of two tables that are included as Supporting Information (Table S1 and Table S2) in the revised manuscript.

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This work study a relevant problem related to the pharmacokinetics of N-acetyl DL-leucine enantiomers that has been used for vertigo treatment as an over the counter drug, essentially in France. The results suggest that during chronic administration of the racemate, the D enantiomer accumulate inducing negative effects. When N-acetyl L-leucine is administered the dose proportionality suggests saturable processes affecting uptake and metabolism. These results are explained by inhibition of uptake at an intestinal carrier of the L-enantiomer by the D-enantiomer, and by metabolism of the L-, but not D-enantiomer, likely by deacetylation. The enantiomers of N-acetyl-leucine exhibit large, unexpected differences in pharmacokinetics supporting the use of N-acetyl-L-leucine instead of the racemate or N-acetyl-D-leucine.

Introduction provides scarce information regarding the use and actions of N-acetyl DL-leucine, some considerations about its potential mechanism of action for the vertigo treatment will be welcome by readers.

Diverse corrections particularly reorganization of the manuscript and figures is needed.

Punutal observations

Response: We have added a section on the potential mechanisms of action of N-acetyl DL-leucine in the treatment of vertigo on lines 54-63 in the revised manuscript.

(Note: We take the word 'punutal' to be a typo, but if it has meaning, please clarify.)

Rows 66-67. This statement is true only for vertebrates, the insects have essentially D amino-acids so please in the sake of knowledge introduce this clarification

Response: Although there are free D-amino acids in all organisms that come from diet or metabolism and play roles of toxins or signalling molecules, and certain peptides (defined as chains with \< 50 amino acids) such as toxins and hormones contain D-amino acids, we are referring to proteins (defined as chains with \> 50 amino acids) synthesized by mRNA. We cannot find any evidence to the contrary that proteins synthesized on ribosomes and encoded by mRNA contain all L-amino acids, even in insects (See Kriel G. 1997. D-amino acids in animal peptides. Annu. Rev. Biochem. 66:337--45). The rare exceptions involve enzymatic post-translational modification. We have modified the sentence in the revised manuscript on lines 90-92 to include the qualifier 'synthesized by ribosomes' to remove this confusion.

Rows 140-141. Please be more specific. In which sense do recording of clinical signs or behaviors of animals minimize suffering?

Response: We have added an explanation in lines 177-179 in the revised manuscript.

Row 153 In which case the tissue was not collected from animals. Please clarify this point.

In some animals only blood/plasma samples were collected, whereas in other animals tissue (skeletal muscle and brain) was collected. This has been clarified by the addition of text in lines 230-232 in the revised manuscript.

Row 159. Sample size is minimal acceptable thus statistical potency of the results low.

Response: Since repeated measurements along time were performed and only 3 data for each point a further analysis about statistical significance should be included, also authors should consider use of other tests such as repeated measurements ANOVA and post hoc tests.

Our primary outcome was changes in pharrmaokinetics determined by parameters such as Cmax, AUC and kel. Our sample size (n=3) was sufficient to yield statistical significance. This sample size is common in pharmacokinetic studies (Gabrielsson2016). We are interested in large, biologically, pharmacologically relevant effect; as we detected these with n=3, we are not concerned with smaller effects, which would be revealed by increasing sample size. It is useful to note that a test statistic is the product of sample size and effect size (Kühberger2015), in other words, p = f (ES, N), the effect size in these experiments was large enough to achieve a low p value (Kühberger2015). Therefore, if the effect size is small but the sample size very large, p will be small and therefore statistically significant. Conversely, if the effect size is large and the sample size small, p will also be small. For identical p values, given equal alpha levels, the probability of committing a Type I (false positive) error is the same regardless of sample size (Kühberger2015). That is, small sample requires a greater treatment effect than a large sample to obtain an equal level of statistical significance. Moreover, the mathematics of the significance test takes into account the sample size (Wilkinson1997). Indeed, Bakan (1966) stated that readers of research results need not adjust obtained significance levels according to sample size, for sample size has already been taken into consideration in the computation of the obtained significance levels. A larger sample size decreases the probability of committing a Type II error (false negative), which is not our concern given the effect sizes we have detected.

We did not use a repeated measures design, as 3 separate mice were used at each time point. Therefore, a repeated measures analysis is not appropriate. Moreover, ANOVA is not optimal as it doesn't detect trends over time. Much preferred is to fit the data to a model, in this case a non-compartmental pharmacokinetics model (Gabrielsson2016). Doing so enables all points to contribute to the pharmacokinetic parameters. The parameters derived from the plasma vs time curve are what are conventionally analysed and statistically compared in pharmacokinetic analysis (Gabrielsson2016).

Please note that all our experiments have followed well-established and standard analysis for pharmacokinetic experiments and analysis (see Gabrielsson2016).

References:

Kühberger A, Fritz A, Lermer E, Scherndl T. 2015. The significance fallacy in inferential statistics. BMC Res Notes. 2015 Mar 17;8:84. doi: 10.1186/s13104-015-1020-4.

Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Fifth. Stockholm: Apotekarsocieteten; 2016.

Wilkerson M and Olson MR. 1997. Misconceptions about sample size, statistical significance, and treatment effect. The Journal of Psychology, 131:6, 627-631, DOI: 10.1080/00223989709603844

Bakan, D. 1966.The test of significance in psychological research. Psychological Bulletin, 66, 423-437.

More details about experimental design are needed since authors did not mention any positive or negative controls, also information about why they decided those timings for the samplings of the drug and also information about who they handled the tissues of the animal is needed.

Response: Again, please note that we have followed well-established and standard analysis for pharmacokinetic experiments and analysis (Gabrielsson2016). A negative control such as a placebo would be important for a pharmacodynamic experiment, but it is unclear how this would be appropriate or how it would be informative in a pharmacokinetic experiment. It is not clear what would constitute a positive or negative control in a pharmacokinetics study.

The timings were informed based on general parameters expected for oral absorption and elimination of typical small-molecule drugs. These timings are consistent with the pharmacokinetics of the racemate in humans, for which oral absorption results in detectable drug in the plasma at 15 min and is relatively slow followed by elimination with a half-life of 1-1.8 hours (Neuzil et al. 2002). Moreover, by virtue of the very data themselves, the timings are appropriate as values are obtained from which the desired pharmacokinetic parameters have been calculated, which was the objective of the study.

Authors refer to plasma samples but not tissue samples. So it is not clear at all who they measured and compared brain and muscle concentrations of the drug. Only in lines 265-269 some mention of this is done.

Add information.

Response: We have added a description of when the tissues were taken and processed in lines 230-232 in the revised manuscript.

Figure 4 is referred after figure 5 in the text. Please invert the order.

Response: We have inverted the order of the figures as requested in the revised manuscript.

Line 398, seems something is lacking \"accounted for the by increase in Cmax\"

Response: The wording was as we intended; however, as the reviewer's response indicates that we were unclear, we have re-worded the sentence in the revised manuscript and hope the logic is now clear. The logic is that as AUC is the product of concentration and time, and when the rate of loss is the same (as in this case), the AUC is entirely dependent on where the decrease starts, which is dictated by Cmax.

Figure 3. The use of letters as symbols in the graphs is confusing and do not contribute to figure compression in fact it is cumbersome and did not allow comparison of the curves (same for figure 4).

Response: We disagree. The use of this type of graphic is to prevent the need for 'decoding' when looking at graphs. We adhere to and agree with the arguments against "encoded legends" and abide by the philosophy and practice that "every visual element contributes directly to understanding". These principles of visual display are explained in detail by Tufte in 'The Visual Display of Quantitative Information" and by John Tukey in \"Exploratory Data Analysis\".

figure 5 What is being compared in h, i and j.

Figure 5. What is being compared in h, i and j?

Response: The plotted values compared to the expected value. This is described in the legend for h and i. We missed stating the same for j, and have now added this text.

In figure 6 in Y Axes Use mg instead of ng

Response: Using mg would seem inappropriate. We assume the reviewer meant microgram? We thought deeply about what units to use, and although changing units would result in less clutter on some of the graphs (fewer zeros), one would have to decode and think about each set of numbers. This is similar to the arguments made for using abbreviation to save space, but in fact require more thought and interruption of the meaning (See: Tufte in 'The Visual Display of Quantitative Information"). We decided to use ng/mL throughout the manuscript for complete internal consistency and to enable immediate and obvious comparisons between all the data in the paper.

Use of letters for symbols in the graphs seems not adequate it makes impossible to read value in brain for L and symbols are one in top of the other. Maybe use of bars would be adequate to rearrange this graphs and the whole figure.

Response: Again, we disagree and prefer to maintain the graphs as they are, to enable rapid and obvious comparison between the D and L, which is the primary objective. Changing the symbol from a letter to a square or circle does not solve the reviewer's criticism, as the symbols would still overlap. Should a reader want to compare very small and accurate values, we have now provided all raw data in the Supporting Information.

Reviewer \#2: The manuscript titled "Unexpected differences in the pharmacokinetics of N-acetyl DL-leucine enantiomers after oral dosing and their clinical relevance" by Strupp and colleagues details the pharmacokinetics of the racemate (N-acetyl-DL-leucine) or the nearly purified active L-enantiomer (N-acetyl-L-leucine) in mice. N-acetyl-leucine, as a racemic mixture, has been used as an over the counter anti-vertiginous drug and has also more recently been utilized in cerebellar ataxia, migraine, lysosomal storage disorders, and with age-related neural issues in the elderly. Recent evidence in animal models have indicated that the effectiveness of N-acetyl-DL-leucine is likely attributed to the L-enantiomer, N-acetyl-L-leucine. However, much is still to be worked out regarding the mechanism of action, pharmacodynamics, and particularly pharmacokinetics -- all aspects of modern-day drug development that would further facilitate the use of N-acetyl-L-leucine or related analogs for treatment of the aforementioned medical issues, as well as possible improve their overall effectiveness. The data in this manuscript convincingly demonstrate that the pharmacologically active form N-acetyl-L-leucine has fundamentally different pharmacokinetics when given as a 50:50 racemate (N-acetyl-507 DL-leucine) when compared to administration of purified preparation containing mostly L-enantiomer and small amounts of the D-isomer. The pharmacokinetic results are consistent with probable inhibition of intestinal uptake of N-acetyl-L-leucine by N-acetyl-D-leucine in conjunction with selective first-pass metabolism of N-acetyl-L-leucine. Low levels of N-acetyl-L-leucine in the brain and muscle, even in the case of N-acetyl-L-leucine administration alone, suggest that N-acetyl-L-leucine may work as a prodrug that gives rise to the active agent upon metabolism. That metabolite is currently unidentified. The paper is reasonably well written and the data are statistically sound and clearly presented. Some statements need to be rephrased to improve clarity. I have listed only one moderate concern and several minor concerns below:

Moderate concern:

What is the rationale or motivation for using Balb/c mice? In light of recent concerns about sex as a biological factor, why were males mice only included in this study? How applicable are the pharmacokinetic data in mice to that in humans? Consider elaborating some of these details in the material and methods and/or discussion.

Response: These are very broad questions that are applicable to all pharmacokinetics studies in general and beyond the scope of our study. We have addressed these questions in the revised manuscript in a new paragraph (lines 202-210 in the revised manuscript by pointing the reader to the relevant literature and what is considered standard practice in the field.

Minor issues:

Abstract as it appears in the main body of the manuscript is incomplete in the abstract box on the title page. The first few sentences are missing. Not sure if this is was a post-uploading issue or inadvertent deletion from the authors.

Response: The same abstract is now present in both locations.

Abstract, pg 2, ln 49: Consider changing "...support the research and development of isolated N-acetyl-L-leucine" to "support the research and development of using only N-acetyl-L-leucine".

Response: We have altered the wording as suggested in the revised manuscript.

Introduction, pg 3, Ln 55: Consider changing "as it is a" to "as a".

Response: We have altered the wording as suggested in the revised manuscript.

Introduction, pg 3, Ln 56: Consider changing "cerebella" to "cerebellar".

Response: We corrected the typo in the revised manuscript.

Introduction, pg 3, Ln 61: For clarity, consider rewriting "As N-acetyl-leucine is an analogue of the alpha amino acid leucine, it has a stereocentre and thus a pair of enantiomers" to "N-acetyl-leucine, an analogue of the alpha amino acid leucine, has a stereocentre and thus a pair of enantiomers".

Response: We were trying to emphasize that the chirality of N-acetyl-leucine stems from the parent amino acid having a stereocentre and was not introduced by N-acetylation. We have reworded the sentence to clarify our meaning in the revised manuscript.

Introduction, pg 4, Ln 80: Consider changing "...from nice to know to effectively need

to know for informed dosing..." to "...from a "nice to know" to effectively "need

to know" basis for informed dosing..."

Response: We have altered the wording as suggested in the revised manuscript.

Introduction, pg 4, Ln 81-82: Consider simplifying "...it was and continues to be marketed as a racemate..." to ""...it was and continues to be used and marketed as a racemate..."

Response: We have altered the wording as suggested in the revised manuscript.

Introduction, pg 4, Ln 88-89: Consider inserting that and at in the following sentence: "each with distinct properties with one (N-acetyl-D-leucine) at best that does not contribute to the therapeutic response, and at worst is potentially responsible for toxicity, as this inactive enantiomer provides 'therapeutic ballast'

Response: We have altered the wording as suggested in the revised manuscript.

Please elaborate on what you mean with the term "therapeutic ballast". Is that synonymous with isomeric ballast?

Response: We have reworded this by adding the phrase 'isomeric ballast', which was coined by Ariens, and deleted the phrase 'therapeutic ballast' taken from the review by Lees. We also added a quotation from the Lees review that elaborates on the meaning. These changes appear on lines 112-118 in the revised manuscript.

Introduction, pg 4, Ln 96: Should "pharmacokinetic" be "pharmacokinetics"?

Response: Yes. We have corrected this typo in the revised manuscript.

MandM, pg 6, ln 141: Should "...distress, clinical signs and general behaviour of the

animals was recorded..." be "distress, clinical signs and general behaviour of the

141 animals were recorded..."

Response: We have corrected the verb tense in the revised manuscript.

MandM, pg 7, ln 153: "where no (ssue samples..." should be "where no tissue samples\".

Response: We have corrected the typo in the revised manuscript.

MandM, pg 11, ln 248: Consider changing "quantitated" to "quantified".

Response: We have changed the word in the revised manuscript.

Results, pg 13, ln 302: Consider rewriting "the main elimination was over for all enantiomers at around 2 h" as the elimination for the D-isomer is closer to four hours.

Response: We have changed 2 to 4 in the revised manuscript.

Results, pg 13, ln 326: "was the plasma is significantly higher" to "in the plasma is significantly higher".

Response: We have corrected the typo in the revised manuscript.

Results, pg 15, ln 344: delete "compared" from "Another way to compare administration of the racemate compared to the purified enantiomer..." to read "Another way to compare administration of the racemate to the purified enantiomer..."

Response: We have corrected the typo in the revised manuscript.

Consider adding superscript asterisks to table to indicate level of significance on values where statistical tests were performed and are relevant.

Response: The table is provided as a reference for all the pharmacokinetic constants. As we made comparisons between two compounds in two formulations, there are six possible comparisons, of which we performed those that were scientifically sensible -- that is, to reveal differences and interactions. It is very cumbersome to convey more than two comparisons in a table. Therefore, our statistical analyses are presented in Figure 5, where we can indicate the specific comparisons with lines and provide exact p values.

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Remove my information/details). Please contact the publication office if you have any questions.
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Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Unexpected differences in the pharmacokinetics of N-acetyl DL-leucine enantiomers after oral dosing and their clinical relevance

PONE-D-19-24169R1

Dear Dr. Churchill,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.
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With kind regards,

Nicolás Pérez-Fernández

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I suggested a change in the figure presentation but authors decided not to follow that recommendation.

I recommend the authors to review the work from:

Calin-Jageman RJ, Cumming G. Estimation for Better Inference in Neuroscience. eNeuro. 2019 Aug 1;6(4). pii: ENEURO.0205-19.2019.

Reviewer \#2: I thank the authors for addressing most of my concerns. I only have a few minor suggestions:

Pg. 4, Ln 90: insert \"a\" before \"nice to know\"; hyphenate \"nice-to-know\" and \"need-to-know\".

Pg. 7, Ln 154: \"Noninvasively\" should be \"noninvasive\".

Pg. 8, Ln 174: Consider changing \"because this inbred strain of mice as it commonly used\" to read \"\...because this inbred strain of mice is commonly used\...\"

Figure Legend 3: Consider stating that \"Plotted values at each time point are the mean +/- SEM from three mice\". Repeat similar phrasing in other figure legends. Otherwise it suggest that only three mice were used for the total plot.

Pg. 19, Ln 434: Consider inserting \"likely\" before \"interfering\".

Pg. 20, Ln 460: Change the \"a\" after \"capacity\" to a comma.

Pg. 20, Ln 462, \"acids are taken up\....\" should be \"acids taken up\...\"

Pg. 20, Ln 480: Should \"acylase\" be \"acetylase\"?

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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